Octapharma

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Ge

Retrieved on: 
Wednesday, January 17, 2024

The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.

Key Points: 
  • The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.
  • The results provide compelling evidence for the use of regular prophylaxis in people with VWD.
  • "The new data from the WIL-31 study provide strong evidence for the use of wilate® prophylaxis in people with all types of VWD.
  • In such instances, indirect treatment comparisons can be used to compare the effects of different treatments.

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, January 3, 2024

PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex®) is now available. The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.

Key Points: 
  • The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.
  • Octapharma has the Balfaxar® production flexibility to ensure consistent supply for hospitals and medical providers.
  • "Octapharma has the production flexibility to ensure consistent supply for hospitals and medical providers now and in the future.
  • Balfaxar® met the primary endpoint of hemostatic efficacy in patients on a vitamin K antagonist undergoing urgent surgery with significant bleeding risk.

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Octapharma USA Presents Factor Concentrates for Perioperative Bleeding Symposium for ASA Annual Meeting Attendees

Retrieved on: 
Tuesday, October 10, 2023

PARAMUS, N.J., Oct. 10, 2023 /PRNewswire/ -- Octapharma USA will sponsor the scientific symposium, Factor Concentrates for Perioperative Bleeding – Global Perspectives, Sunday, October 15th in conjunction with the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco.

Key Points: 
  • PARAMUS, N.J., Oct. 10, 2023 /PRNewswire/ -- Octapharma USA will sponsor the scientific symposium, Factor Concentrates for Perioperative Bleeding – Global Perspectives, Sunday, October 15th in conjunction with the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco.
  • The symposium will address current gaps in research related to factor concentrates, including prothrombin complex concentrates (PCC) and fibrinogen concentrates (FC), for perioperative bleeding management.
  • Kamrouz Ghadimi, MD, MHSc, Department of Anesthesiology, Duke University, will discuss, "Perioperative Coagulopathic Bleeding – Definition, Treatment Algorithms, and POC Testing, Oh My!"
  • The role of factor concentrates and blood products for management of bleeding in surgery;
    The latest research and current practice guidelines for factor concentrates in perioperative bleeding; and
    Individualized bleeding management strategies in cardiac surgery, with patient case presentations.

Advancements in Hemophilia Treatment Propel Global Bleeding Disorders Market to New Heights by 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 2, 2023

This growth is driven by rapid advancements in bleeding disorder treatments, an increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders, and government initiatives to support hemophilia management.

Key Points: 
  • This growth is driven by rapid advancements in bleeding disorder treatments, an increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders, and government initiatives to support hemophilia management.
  • Bleeding disorders encompass a group of conditions characterized by abnormal bleeding due to deficiencies or dysfunction in certain clotting factors in the blood.
  • Several factors are contributing to the growth of the bleeding disorders market, including:
    Rapid advancements in bleeding disorder treatment.
  • North America holds a major share of the bleeding disorders market, while Asia-Pacific is expected to witness the highest CAGR.

Heroes in the Fight: Octapharma To Be Honored for Myositis Research at TMA Annual Patient Conference

Retrieved on: 
Wednesday, September 6, 2023

PARAMUS, N.J., Sept. 6, 2023 /PRNewswire/ -- Octapharma USA will be presented with the Research & Development Award for Outstanding Innovation in Myositis Research during the Heroes in the Fight Awards Celebration at The Myositis Association's 2023 International Annual Patient Conference to be held September 7 - 10 in San Diego.

Key Points: 
  • "TMA is grateful to Octapharma for being the first pharmaceutical company to take the chance on a treatment for this rare autoimmune disease of the muscles.
  • "We are honored to be recognized by TMA for Octapharma's groundbreaking research on dermatomyositis," said Octapharma USA President Flemming Nielsen.
  • "TMA and Octapharma are celebrating special anniversaries this year, and we congratulate TMA on 30 great years serving the myositis community.
  • Octapharma is the Premier Sponsor for the conference, which features myositis specialists and expert presenters on everything related to these debilitating diseases.

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.

Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, July 26, 2023

Balfaxar® helps restore blood coagulation by replenishing the levels of clotting factors that are deficient due to warfarin therapy.

Key Points: 
  • Balfaxar® helps restore blood coagulation by replenishing the levels of clotting factors that are deficient due to warfarin therapy.
  • The Phase III, randomized, double-blind, multicenter study was performed at 24 sites in the U.S. and Europe and randomized 208 patients to Balfaxar® (N=105) or control 4F-PCC (N=103).
  • We are confident Balfaxar® will be a welcomed treatment for physicians who need to quickly restore patients' coagulation."
  • Balfaxar®, a lyophilized powder for reconstitution, will be provided with sterile water for injection and the new transfer device, nextaro ®.

EQS-News: Board of Directors and Managing Directors of SNP with neutral statement on voluntary public takeover offer

Retrieved on: 
Friday, July 7, 2023

Taking into account the different valuation options of the offer, they refrain from making a recommendation to the SNP shareholders (so-called “neutral statement").

Key Points: 
  • Taking into account the different valuation options of the offer, they refrain from making a recommendation to the SNP shareholders (so-called “neutral statement").
  • The Board of Directors and the Managing Directors do not see any synergy potentials due to the different focus and corporate purpose of the bidder compared to SNP.
  • The detailed terms and conditions of the voluntary public takeover offer can be found in the offer document.
  • Please note that only the joint reasoned statement of the Board of Directors and the Managing Directors is authoritative.